Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.
Stopping Beta-Blockers Safe 1 Year Post MI For Stable Patients
Discontinuing beta-blocker therapy was found to be noninferior to continuing the therapy among stable, low-risk patients who took it for at least one year post myocardial infarction (MI), according to the SMART-DECISION trial presented at ACC.26 and simultaneously published in NEJM.
Evolocumab Cuts CV Risk in Diabetes Without ASCVD
The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented at ACC.26 and simultaneously published in JAMA.
Sirolimus-Coated vs. Uncoated Balloons For Infrainguinal Artery Disease
For patients with symptomatic infrainguinal artery disease, angioplasty with a sirolimus-coated balloon, vs. an uncoated balloon, reduced major adverse limb events at one year, according to the SirPAD trial presented at ACC.26 and published simultaneously in NEJM.
Sotatercept Significantly Benefits Patients With CpcPH, HFpEF
Sotatercept was associated with significant improvements in blood pressure and vascular health in patients with heart failure with preserved ejection fraction (HFpEF) and severe combined post and precapillary pulmonary hypertension (CpcPH), according to results of CADENCE presented at ACC.26 and simultaneously published in Circulation.
ACC.26 Hub
Visit ACC.org/ACC2026 for all the meeting coverage.
Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Lipid Metabolism, Nonstatins, Novel Agents, Statins, Acute Heart Failure, Pulmonary Hypertension, Hypertension
Keywords: Cardiology Magazine, ACC Publications, CM-May-2026, Adrenergic beta-Antagonists, ACC Annual Scientific Session, ACC26, New Orleans, Myocardial Infarction, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol, LDL, PCSK9 Inhibitors, Ischemic Stroke, Diabetes Mellitus, Atherosclerosis, Ischemia, Hypertension, Hypertension, Pulmonary, Peripheral Arterial Disease, Heart Failure, Pulmonary Wedge Pressure, Blood Pressure, Atrial Pressure, Pulmonary Artery, Stroke Volume
